|Key people||Paul Kemp (CEO) John Lovelady (COO)|
|Products||1 in clinical development|
Intercytex was originally founded in 2000 and listed on the Alternative Investment Market in February 2006, as Intercytex Group plc. As a result of the recession and disappointing trial results with another product, Intercytex plc delisted from AIM in 2009 and was forced to sell all of its assets. Intercytex Ltd and VAVELTA were purchased by a private concern, Regenerative Solutions Ltd, which is now the holding company. Today Intercytex is funded in part by a series of grants from the North West Development Agency, the UK Government's Technology Strategy Board, the European Union and by an agreement with the US Department of Defence as well as private investment. Intercytex Ltd is focused on developing and marketing VAVELTA to ensure its potential and benefits can be realised. In 2011 Intercytex launched its Cell2Therapy service which is providing ATMP Translational Services for other companies.
Currently the company doesn't have a marketed product, though its pipeline includes a drug in phase II clinical development, designated in the EU as an ATMP (Vavelta/ICX-RHY). The table shows products originally under development by Intecytex plc and subsequently sold during the company's reorganisation in 2009–2010
|VAVELTA||Phase II clinical trial||Epidermolysis Bullosa and scar contracture repair||Intercytex Ltd|
|cyzact||failed in Phase III clinical trial, sold||Active repair in chronic wounds||Healthpoint Biotherapeutics|
|ICX-TRC||Phase II clinical trial, sold||Hair regeneration||Aderans Research Institute|
|ICX-SKN||Phase I clinical trial, sold||Skin graft replacement||Healthpoint Biotherapeutics|